## Direct Assistance

<table>
<thead>
<tr>
<th>BUDGET CATEGORIES</th>
<th>PREVIOUS AMOUNT (A)</th>
<th>AMOUNT THIS ACTION (B)</th>
<th>TOTAL (A + B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Fringe Benefits</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Travel</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Equipment</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Supplies</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Contractual</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Construction</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Other</td>
<td>$0.00</td>
<td>$2,344.00</td>
<td>$2,344.00</td>
</tr>
<tr>
<td>Total</td>
<td>$0.00</td>
<td>$2,344.00</td>
<td>$2,344.00</td>
</tr>
</tbody>
</table>
### Federal Financial Report Cycle

<table>
<thead>
<tr>
<th>Reporting Period Start Date</th>
<th>Reporting Period End Date</th>
<th>Reporting Type</th>
<th>Reporting Period Due Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/01/2018</td>
<td>09/30/2018</td>
<td>Annual</td>
<td>12/29/2018</td>
</tr>
<tr>
<td>10/01/2018</td>
<td>09/30/2019</td>
<td>Annual</td>
<td>12/29/2019</td>
</tr>
<tr>
<td>10/01/2019</td>
<td>09/30/2020</td>
<td>Annual</td>
<td>12/29/2020</td>
</tr>
<tr>
<td>10/01/2020</td>
<td>09/30/2021</td>
<td>Annual</td>
<td>12/29/2021</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>09/30/2022</td>
<td>Annual</td>
<td>12/29/2022</td>
</tr>
<tr>
<td>10/01/2022</td>
<td>08/31/2023</td>
<td>Final</td>
<td>11/29/2023</td>
</tr>
</tbody>
</table>
1. Terms and Conditions
2. Technical Review
Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at https://www.cdc.gov/grants/federalregulationspolicies/index.html, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CDC-RFA-DP18-18105, entitled Provision of Technical Assistance and Training Activities to Assure Comprehensive Cancer Control Outcomes, and application dated May 30, 2018, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of $354,000 is approved for the Year 02 budget period, which is September 1, 2019 through August 31, 2020. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

I. Technical Assistance: Provide programmatic, evaluation, epidemiologic, and technical assistance for recipients and their stakeholders and partners through programmatic and one-on-one technical consultation, national training, workshops, Web Conferences, SEALS, and Water Fluoridation Reporting System (WFRS) training, and other forms of guidance. CDC will also facilitate technical assistance between national partners and recipients as needed.

ii. Information Sharing between Recipients: The Program will share information, best practices, lessons learned, and evaluation results among recipients through program list-serv, conferences, guidance, material development, webinars, digital media, participation in appropriate meetings and committees, conference calls and working groups, including “communities of practice”.

iii. Additional Support: CDC will develop technical assistance resources for recipients through cooperative agreements with national organizations.
Technical Review Statement Response Requirement: The review comments on the strengths and weaknesses of the proposal are provided as part of this award. A response to the weaknesses in these statements must be submitted to and approved, in writing, by the Grants Management Specialist/Grants Management Officer (GMS/GMO) noted in the CDC Staff Contacts section of this NoA, no later than 30 days from the budget period start date. Failure to submit the required information by the due date, October 1, 2019, will cause delay in programmatic progress and will adversely affect the future funding of this project.

Budget Revision Requirement: By October 1, 2019 the recipient must submit a revised budget with a narrative justification based on approved funding. Recipient must submit notification of contractor amendment in GrantSolutions for TBD Contractors. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

Direct Assistance (DA): DA is awarded in the amount of $2344 for SAS License in this budget period.

Expanded Authority: The recipient is permitted the following expanded authority in the administration of the award.

☒ Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 “Remarks” of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient’s authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

Program Income: Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

Addition alternative: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

FUNDING RESTRICTIONS AND LIMITATIONS

Indirect Costs: Indirect costs are approved based on the negotiated indirect cost rate agreement dated March 9, 2018, which calculates indirect costs as follows, a Provisional is approved at a rate of 21.30% of the base, which includes, direct salaries and wages including all fringe benefits. The effective dates of this indirect cost rate are from July 1, 2019 to June 30, 2022.

REPORTING REQUIREMENTS
Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Monique Tatum, Grants Management Specialist
Centers for Disease Control and Prevention
Chronic Disease and Birth Defect Services Branch
2939 Flowers Road South MS-TV-2
Atlanta, Georgia 30341
Email: mtatum@cdc.gov (Include “Mandatory Grant Disclosures” in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include “Mandatory Grant Disclosures” in subject line) or Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and
cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

**Payment Management System Subaccount:** Funds awarded in support of approved activities have been obligated in a newly established subaccount in the PMS, herein identified as the “P Account”. Funds must be used in support of approved activities in the NOFO and the approved application. All award funds must be tracked and reported separately.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

### CDC STAFF CONTACTS

**Grants Management Specialist:** The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

**GMS Contact:**
Monique Tatum, Grants Management Specialist
Centers for Disease Control and Prevention
Chronic Disease and Birth Defect Services Branch
Telephone: 770-488-2617
Email: mtatum@cdc.gov

**Program/Project Officer:** The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

**Programmatic Contact:**
Monique Brown, Project Officer
Centers for Disease Control and Prevention
NCCDPHP-DCPC
4770 Buford Hwy
Atlanta, GA 30341
Telephone: 404-639-0925
Email: MCBrown1@cdc.gov

**Grants Management Officer:** The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.
I. Annual Performance Report (September 1, 2018 – February 28, 2019)

Key Strengths:
- The applicant successfully completed contracts necessary to fulfill the requirements of the cooperative agreement. Five of six letters of agreement/contracts have been signed and activities are in the beginning stage of implementation.
- The Basic Screening Survey is nearly complete. A total of 53 schools participated in the screening and most screening forms have been received. (Note: Recipient started BSS process prior to DP18-1810 award).

Key Weaknesses:
- Hiring personnel has taken longer than expected, resulting in expected excess funds of approximately $57K.

Key Recommendations:
- Recipient should consider budget revision and reallocation of funds due to delays in hiring.
II. Year 2 Proposed Work plan

Key Strengths:
- The work plan is within the scope of the NOFO and supports achievement of the performance measures.

Key Weaknesses:
- The work plan does not include the development of required document, Fluoridation Status of Community Water Systems/Water Fluoridation Equipment Assessment, by the end of project year 2.

Key Recommendations:
- Revise work plan to include activities to support development of a Water Fluoridation Equipment Assessment.
- CDC will provide feedback and technical assistance to awardees to finalize the year two work plan and performance targets post award.
- CDC Program Support to Awardees: CDC will consider comments made in the Annual Performance Report regarding CDC support for awardees. Analysis of these comments will be used to improve the quality of trainings, technical assistance, and support to grantees to overcome any challenges to achieve complete activities outlined in the work plan, and annual project period outcomes and performance measures.

III. Year 2 Proposed Budget

Comments:
- Proposed budget narrative is consistent with the budget request for $354,000.
- Include 6 required components for contracts in accordance with the Office of Financial Resources Budget Preparation Guidelines for contracts in the amount of $143,578.
- Revise budget to include any costs associated with activities to conduct the Fluoridation Status of Community Water Systems/Water Fluoridation Equipment Assessment.
- Consider reallocation of funds to include participation of staff responsible for Sealants and CWF to attend the National Oral Health Conference.